|
|
|
|
|
Sponsors and Collaborators: |
Dana-Farber Cancer Institute National Cancer Institute (NCI) |
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00003045 |
RATIONALE: Hyperthermia therapy may kill prostate cancer cells by heating them to several degrees above body temperature. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining hyperthermia with radiation therapy may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of hyperthermia plus radiation therapy in treating patients who have nonmetastatic advanced prostate cancer.
Condition | Intervention | Phase |
Prostate Cancer |
Procedure: hyperthermia treatment Procedure: radiation therapy |
Phase II |
MedlinePlus related topics: | Cancer Fever Prostate Cancer |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | A Phase II Trial of Hyperthermia and Radiotherapy for Locally Advanced Adenocarcinoma of the Prostate |
Estimated Enrollment: | 65 |
Study Start Date: | April 1997 |
OBJECTIVES:
OUTLINE: Patients are treated with external beam irradiation 5 days a week for a total of approximately 7 weeks. Hyperthermia treatment is given twice in the first 4 weeks of radiation therapy, preferably early in the course of radiation. Hyperthermia treatments are only given once a week. A transrectal ultrasound applicator is used to deliver the hyperthermia treatment.
Patients are followed every three months for 2 years, and every 6 months thereafter.
PROJECTED ACCRUAL: Approximately 65 patients will be accrued over 2 years.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Cardiovascular:
Neurologic:
Pulmonary:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
Other:
United States, Massachusetts | |||||
Dana-Farber Cancer Institute | |||||
Boston, Massachusetts, United States, 02115 | |||||
Joint Center for Radiation Therapy | |||||
Boston, Massachusetts, United States, 02215 |
Dana-Farber Cancer Institute |
National Cancer Institute (NCI) |
Study Chair: | Mark Hurwitz, MD | Dana-Farber Cancer Institute |
Clinical trial summary from the National Cancer Institute's PDQ® database 
  |
Study ID Numbers: | CDR0000065679, DFCI-94153, NCI-H97-1294 |
First Received: | November 1, 1999 |
Last Updated: | July 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00003045 |
Health Authority: | United States: Federal Government |
|
|
|
|